Differences in the effectiveness of treatment of cholelithiasis and biliary sludge with various drugs of ursodeoxycholic acid
- Authors: Vyalov S.S1,2
-
Affiliations:
- People’s Friendship University of Russia
- N.E.Bauman Moscow State Technical University
- Issue: Vol 19, No 8-2 (2017)
- Pages: 64-68
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/94650
- DOI: https://doi.org/10.26442/2075-1753_19.8.2.64-68
- ID: 94650
Cite item
Full Text
Abstract
Purpose: comparative analysis of clinical efficacy of ursodeoxycholic acid drugs for treatment of cholelithiasis and biliary sludge. Materials and methods. A retrospective multicenter study of 5 thousand patients was conducted, in which the actual occurrence of various stages of cholelithiasis in clinical practice was assessed. The effectiveness of treatment of cholelithiasis and biliary sludge in 210 patients receiving ursodeoxycholic acid therapy was evaluated. Results. Analysis of the patients structure on an outpatient visit revealed a frequency of cholelithiasis morbidity 15.5%. The prevalence of mild forms of cholelithiasis was 9.3%. The greatest effectiveness of reducing the size of gallstones and biliary sludge symptoms according to the results of the study was noted in the group whose participants took Ursosan. Conclusion. Сhoosing a treatment it is necessary to take into account the peculiarities of ursodeoxycholic acid preparations, the quality of production and substance. Ursosan may be a drug of choice for therapy of cholelithiasis.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
S. S Vyalov
People’s Friendship University of Russia; N.E.Bauman Moscow State Technical University
Email: svialov@mail.ru
канд. мед. наук, доц. каф. общей практики, врач-гастроэнтеролог, гепатолог GMS clinic & hospitals. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6
References
- Heaton K.W, Braddon F.E, Mountford R.A.et al. Symptomatic and silent gall stones in the community. Gut 1991; 32: 316.
- Petroni M.L, Jazrawi R.P, Pazzi P. et al. Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol 2000; 12: 695.
- Festi D., Reggiani M.L., Attili A.F. et al. Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol 2010; 25: 719.
- Вялов С.С., Степченко А.А., Дронова Т.А., Винницкая Е.В. Выбор препарата для лекарственной терапии с учетом особенностей субстанции. Арх. внутренней медицины. 2012; 4 (6): 34-8.
- Warttig S., Ward S, Rogers G, Guideline Development Group. Diagnosis and management of gallstone disease: summary of NICE guidance. BMJ 2014; 349: g6241.
- Festi D., Reggiani M.L, Attili A.F. et al. Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol 2010; 25: 719.
- Berger M.Y., van der Velden J.J, Lijmer J.G. et al. Abdominal symptoms: do they predict gallstones? A systematic review. Scand J. Gastroenterol 2000; 35: 70.
- Guarino M.P, Cocca S., Altomare A. et al. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol 2013; 19: 5029.
- Di Ciaula A, Wang D.Q, Wang H.H. et al. Targets for current pharmacologic therapy in cholesterol gallstone disease. Gastroenterol Clin North Am 2010; 39: 245.
- Минушкин О.Н., Бурдина Е.Г., Новоженова Е.В. Билиарный сладж. Эпидемиология, факторы риска, формирование, диагностика, лечебные подходы. Практич. гастроэнтерология. 2017; 2 (19): 2-4.
- Яковлев А.А., Волков А.С. Клиническая эффективность и безопасность курсовой литолитической терапии больных с хроническим холециститом и билиарным сладжем препаратом Ливодекса. Клин. фармакология. 2015. Вып. 115; 3.
- Сарвилина И.В. Сравнительный клинико-экономический анализ применения препаратов урсодезоксихолевой кислоты у пациентов с желчнокаменной болезнью стадии. Лечащий врач. 2015; 2
Supplementary files
